A prospective case series of Ranibizumab for the treatment of inflammatory and idiopathic choroidal neovascular membranes.

Trial Profile

A prospective case series of Ranibizumab for the treatment of inflammatory and idiopathic choroidal neovascular membranes.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 May 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Choroidal neovascularisation
  • Focus Therapeutic Use
  • Most Recent Events

    • 31 May 2017 New trial record
    • 01 Sep 2016 Status changed from recruiting to completed, according to results published in the British Journal of Ophthalmology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top